naratriptan has been researched along with Pain, Intractable in 1 studies
naratriptan: structure given in first source
Pain, Intractable: Persistent pain that is refractory to some or all forms of treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment of chronic migraine often poses a major challenge to the clinician." | 1.32 | Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. ( Bigal, ME; Feleppa, M; Rapoport, AM; Sheftell, FD; Tepper, SJ; Volcy, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rapoport, AM | 1 |
| Bigal, ME | 1 |
| Volcy, M | 1 |
| Sheftell, FD | 1 |
| Feleppa, M | 1 |
| Tepper, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TreximetTM in the Prevention and Modification of Disease Progression in Migraine[NCT01300546] | Phase 4 | 40 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Self-assessed grade of compliance with lifestyle modification changes (where A=1, B=2, C=3, D=4, and F=5; lower scores represent better outcomes) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Day 121
| Intervention | scores on a scale (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | 2.33 |
| Naproxen Sodium | 2.43 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Days 91-120 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Day 121 (following 30 day Baseline Period and Treatment Period Days 91-120)
| Intervention | percent change of headache days (Mean) |
|---|---|
| Sumatriptan/Naproxen Sodium | -13.50 |
| Naproxen Sodium | -36.50 |
Total number of doses of study medication reported taken per participant in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | doses of study medication (Mean) | ||
|---|---|---|---|
| Treatment Period Month 1 | Treatment Period Month 2 | Treatment Period Month 3 | |
| Naproxen Sodium | 9.36 | 8.86 | 8.50 |
| Sumatriptan/Naproxen Sodium | 11.00 | 10.28 | 10.28 |
Number of subjects with at least a 50% reduction in number of headache days reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 3 | 3 | 6 |
| Sumatriptan/Naproxen Sodium | 1 | 2 | 3 |
Comparing the number of migraine attacks reported from Baseline to the number of migraine attacks reported in Treatment Period Months 1(Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Each treatment month percent change was individually compared to Baseline. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (total migraine attacks days during Treatment Period Month 3 (Days 91-120)-total migraine attacks during Baseline (Days 1-30)/total migraine attacks during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine attacks (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -12.23 | -9.03 | -39.12 |
| Sumatriptan/Naproxen Sodium | -4.35 | -2.88 | -8.63 |
Number of subjects with at least a 50% reduction in number of migraine attacks reported in Baseline versus Treatment period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 1 | 0 | 6 |
| Sumatriptan/Naproxen Sodium | 3 | 2 | 4 |
"Change in MIDAS total score from end of Baseline (Day 31) to end Treatment Period month 3 (Day 121) in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Total score of disability ranges:~0 to 5, MIDAS Grade I, Little or no disability~6 to 10, MIDAS Grade II, Mild disability~11 to 20, MIDAS Grade III, Moderate disability~21+, MIDAS Grade IV, Severe disability No subscales are present." (NCT01300546)
Timeframe: Baseline MIDAS collected at Day 31, Post final dose study medication MIDAS collected at Day 121.
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline Day 31 | Day 121 | |
| Naproxen Sodium | 22.6 | 24.1 |
| Sumatriptan/Naproxen Sodium | 28.7 | 27.9 |
Comparing mean migraine duration from onset to painfree from Baseline(Days 1-30) to each month: Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[(mean duration from onset to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from onset to painfree during Baseline (Days 1-30)/mean duration from onset to painfree during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.92 | -26.35 | 70.84 |
| Sumatriptan/Naproxen Sodium | 72.04 | 35.86 | 61.96 |
"% change from Baseline in mean migraine duration from time of treatment to pain free reported in Treatment Period Months 1, 2, and 3 in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm.~Percent change=[(mean duration from treatment to painfree during Treatment Period Month 3 (Days 91-120)- mean duration from treatment to painfree during Baseline (Days 1-30)/mean duration from treatment to painfree during Baseline (Days 1-30)]*100%)." (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine duration (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -14.91 | -25.52 | 73.42 |
| Sumatriptan/Naproxen Sodium | 150.10 | 92.73 | 114.10 |
Comparing migraine severity 2 hours after treatment from Baseline(Days 1-30) to migraine severity reported 2 hours after treatment in Treatment Period Months 1 (Days 31-60), 2(Days 61-90), and 3(Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. Percent change was calculated by determining percent change in each subject, from Treatment Period Month 3 and Baseline, then comparing the average change between each arm. The following formula was used for each treatment period calculation. e.g.,Percent change=[ (mean migraine severity during Treatment Period Month 3 (Days 91-120)- mean migraine severity during Baseline (Days 1-30)/mean migraine severity during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine severity (Mean) | ||
|---|---|---|---|
| 2 hours after treatment for Baseline to Month 1 | 2 hours after treatment for Baseline to Month 2 | 2 hours after treatment for Baseline to Month 3 | |
| Naproxen Sodium | 11.78 | 0.33 | 32.62 |
| Sumatriptan/Naproxen Sodium | -17.84 | -36.71 | -55.60 |
Comparing the number of migraine headache days during Baseline Period Days 1-30 to number or migraine headache days reported in Treatment Period Month 1 (Days 31-60), Treatment Period Month 2 (Days 61-90), and Treatment Period Month 3 (Days 91-120) in Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g., Percent change=[ (total headache days during Treatment Period Month 3 (Days 91-120)-total headache days during Baseline (Days 1-30)/total headache days during Baseline (Days 1-30)]*100%). (NCT01300546)
Timeframe: Baseline Period collected at Day 31, Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of migraine headache days (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | -26.86 | -21.44 | -36.50 |
| Sumatriptan/Naproxen Sodium | -1.70 | -4.39 | -13.50 |
% change in number of doses during Baseline of triptans (Group A) and non-steroidal anti-inflammatory drugs(NSAIDs) (Group B) vs. doses during Treatment Period Months 1, 2, and 3 of study medication in the Sumatriptan/Naproxen Sodium arm vs. Naproxen Sodium arm. e.g.,Percent change=[(number of doses during Treatment Period Month 3 (Days 91-120)- number of doses during Baseline (Days 1-30)/number of doses during Baseline (Days 1-30)]*100%). The total number of subjects used in this analysis is different than the total number of subjects as the analysis is only looking at those subjects that were taking one of the study medications during Baseline. (NCT01300546)
Timeframe: Treatment Period Months 1, 2, and 3 collected at Days 61, 91, and 121.
| Intervention | percent change of study medication (Mean) | ||
|---|---|---|---|
| Baseline to Treatment Period Month 1 | Baseline to Treatment Period Month 2 | Baseline to Treatment Period Month 3 | |
| Naproxen Sodium | 160.8 | 76.4 | 112.7 |
| Sumatriptan/Naproxen Sodium | 130.8 | 114.9 | 96.1 |
1 other study available for naratriptan and Pain, Intractable
| Article | Year |
|---|---|
Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases.
Topics: Adolescent; Adult; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Pain, Intractable | 2003 |